Arek Z. Dudek, MD, PhD

Investigator, Metro-Minnesota Community Oncology Research Consortium

HealthPartners and Regions Cancer Care Centers title

Medical oncologist and hematologist

Joined the Institute



MD, Medical University of Warsaw, Poland; internal medicine residency, Pinnacle Health Hospitals, Harrisburg, PA; fellowship in hematology and oncology, University of Minnesota.

Research highlights

Dr. Dudek has been published more than 100 times in peer-reviewed medical journals for his work in lung cancer, melanoma and kidney cancer. In addition, he has written several editorials and book chapters on topics such as tumor biology and targeted cancer therapies. He serves as a research and clinical mentor to graduate students, junior faculty and clinicians.

Research interests

Dr. Dudek discovered his calling to become a medical oncologist very early in medical school. He found cancer to be one of the most challenging human diseases, requiring the physician to have broad knowledge of all other medical disciplines and an understanding of cellular and molecular biology. The need for development of better therapies for cancer has led Dr. Dudek to look for novel cancer therapeutics and provide them to his patients who participate in cancer clinical trials in the early-phase clinical trials program at Regions Hospital.

Current projects

Dr. Dudek is principal investigator in 12 clinical studies and is currently developing several new clinical trials focused on immune and targeted therapy of cancer. Two examples of his research:

  • Principal investigator, Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination with Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Research Consortium BTCRC-GU14-003. Objective: To test the hypothesis that, through the strategy of adding the anti-VEGF agent bevacizumab to the anti-PD-1 agent pembrolizumab, tumor vasculature can be normalized, resulting in enhanced tumor destruction and longer patient survival.
  • Principal investigator, Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination with Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors. Objective: To determine if the Aurora A kinase inhibitor alisertib enhances the antiangiogenic effects of a VEGF inhibitor, pazopanib, and to determine the optimally tolerated dose of alisertib when used in combination with pazopanib for the treatment of advanced, previously treated solid tumor malignancies.

Publications in PubMed

Contact information

Office: 651-254-3299
Clinic: 651-254-3572
Email: Arkadiusz.Z.Dudek@HealthPartners.Com


Arek Dudek